Trial Profile
A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 27 Feb 2012 Actual patient number (13) added as reported by ClinicalTrials.gov record.
- 27 Feb 2012 Planned end date changed from 1 Aug 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov record.
- 27 Feb 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinjcalTrials.gov.